Neoadjuvant radiotherapy followed by surgery can improve overall survival compared with surgery alone in certain patients with locally advanced rectal cancers, most notably in those with lower rectal ...

In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the ...

Vienna, Austria – Rectal cancer is a type of bowel cancer that develops in the last several centimetres of the large intestine, just before the anus. It’s one of the most common cancers in Europe, ...

GSK announces positive interim results from registrational phase II AZUR-1 trial of Jemperli in dMMR/MSI-H locally advanced rectal cancer: London, UK Tuesday, July 14, 2026, 12:00 ...

A new trial of patients with advanced rectal cancer has found that the addition of immunotherapy treatment alongside extended radiotherapy led to better rates of remission. The findings from the ...

GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), ...

GSK's pivotal AZUR-1 trial of cancer immunotherapy Jemperli, as a way to delay or eliminate surgery in pre-operative rectal ...

In patients with locally advanced rectal cancer who receive neoadjuvant therapy, radiation dose intensification improves pathologic complete response but leads to a small increase in acute toxicities.

Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...